Wall Street analysts expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to post $108.07 million in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Supernus Pharmaceuticals’ earnings. The highest sales estimate is $110.63 million and the lowest is $103.67 million. Supernus Pharmaceuticals posted sales of $88.44 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 22.2%. The business is expected to report its next quarterly earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year sales of $401.02 million for the current financial year, with estimates ranging from $396.63 million to $403.60 million. For the next year, analysts anticipate that the company will post sales of $463.72 million, with estimates ranging from $450.92 million to $472.58 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that that provide coverage for Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.09. The company had revenue of $102.99 million for the quarter, compared to the consensus estimate of $100.75 million. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. Supernus Pharmaceuticals’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.29 earnings per share.
Several research firms have recently weighed in on SUPN. Cantor Fitzgerald restated an “overweight” rating on shares of Supernus Pharmaceuticals in a research report on Friday, November 23rd. ValuEngine downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 6th. BidaskClub downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 7th. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 11th. Finally, Cowen set a $55.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 30th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Supernus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $56.89.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. Glenmede Trust Co. NA lifted its position in Supernus Pharmaceuticals by 3.2% during the second quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock worth $39,070,000 after buying an additional 20,012 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in Supernus Pharmaceuticals by 28.1% during the third quarter. Janney Montgomery Scott LLC now owns 13,860 shares of the specialty pharmaceutical company’s stock worth $698,000 after buying an additional 3,039 shares in the last quarter. Icon Advisers Inc. Co. purchased a new position in Supernus Pharmaceuticals during the third quarter worth approximately $3,877,000. Oppenheimer Asset Management Inc. lifted its position in Supernus Pharmaceuticals by 9.2% during the third quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock worth $746,000 after buying an additional 1,251 shares in the last quarter. Finally, Cynosure Advisors LLC lifted its position in Supernus Pharmaceuticals by 55.0% during the second quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock worth $494,000 after buying an additional 2,930 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.
Shares of SUPN stock opened at $36.53 on Friday. The company has a market cap of $2.40 billion, a price-to-earnings ratio of 28.99, a price-to-earnings-growth ratio of 1.45 and a beta of 0.93. The company has a current ratio of 2.82, a quick ratio of 2.65 and a debt-to-equity ratio of 0.77. Supernus Pharmaceuticals has a 12-month low of $34.90 and a 12-month high of $61.25.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
See Also: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.